Toshiyuki Sumi

41PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsAllergyTumour immunologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (41)

|Aug 16, 2026
Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes.

|May 31, 2026
Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes.

|Feb 19, 2026
Six-Month Benralizumab Maintenance for Relapsing Chronic Eosinophilic Pneumonia Guided by Eosinophil Kinetics.

Toshiyuki Sumi, Taiki Ishigooka, Kazuya Takeda

|Feb 09, 2026
PD-L1 Expression and Histopathological Features in EGFR-Mutated Non-Small Cell Lung Cancer: Implications for Immune Checkpoint Inhibitors After EGFR-Tyrosine Kinase Inhibitors Resistance.

Toshiyuki Sumi, Taiki Ishigooka, Keigo Matsuura

|Jun 30, 2025
Prophylactic Interventions to Prevent Severe Skin Toxicities in Patients With Non-Small Cell Lung Cancer Treated With Nivolumab + Ipilimumab With or Without Chemotherapy.

Toshiyuki Sumi, Kaori Kanamaru, Shunsuke Tsuji

|Jun 30, 2025
Significance of Platinum-Based Chemotherapy With Programmed Death-1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study.

Ayako Shiono, Hisao Imai, Kyoichi Kaira

Pageof 7

Frequent Collaborators

8 joint publications

Naoki Shijubou

2 joint publications

Hirofumi Chiba

1 joint publications

Yuichi Yamada

1 joint publications

Hisashi Nakata